Nayoung Kim , Dong-hee Lee , Woo Seon Choi , Eunbi Yi , Hyojeong Kim , Jung Min Kim , Hyung-seung Jin , Hun Sik Kim
: 생화학분자생물학회(구 한국생화학분자생물학회)
: BMB Reports 54권1호
: 2021년 01월
IMMUNE CHECKPOINT RECEPTORS
CD47, CD73, AND SIGLEC FAMILY PROTEINS
CHIMERIC ANTIGEN RECEPTORS
CAR-NK DEVELOPMENT IN INDUSTRY: CURRENT STATUS
CONCLUSIONS AND PERSPECTIVES
CONFLICTS OF INTEREST
Natural killer (NK) cells, key antitumor effectors of the innate immune system, are endowed with the unique ability to spontaneously eliminate cells undergoing a neoplastic transformation. Given their broad reactivity against diverse types of cancer and close association with cancer prognosis, NK cells have gained considerable attention as a promising therapeutic target for cancer immunotherapy. NK cell-based therapies have demonstrated favorable clinical efficacies in several hematological malignancies but limited success in solid tumors, thus highlighting the need to develop new therapeutic strategies to restore and optimize anti-tumor activity while preventing tumor immune escape. The current therapeutic modalities yielding encouraging results in clinical trials include the blockade of immune checkpoint receptors to overcome the immune-evasion mechanism used by tumors and the incorporation of tumor-directed chimeric antigen receptors to enhance NK cell anti-tumor specificity and activity. These observations, together with recent advances in the understanding of NK cell activation within the tumor microenvironment, will facilitate the optimal design of NK cell-based therapy against a broad range of cancers and, more desirably, refractory cancers. [BMB Reports 2021; 54(1): 44-58]
: 자연과학분야 > 화학
한국학술정보㈜의 모든 학술 자료는 각 학회 및 기관과 저작권 계약을 통해 제공하고 있습니다.
이에 본 자료를 상업적 이용, 무단 배포 등 불법적으로 이용할 시에는 저작권법 및 관계법령에 따른 책임을 질 수 있습니다.